ChemDiv Inc. is a recognized global leader in discovery chemistry with one of the industry's largest, most diverse, and most productive collections of over 1,600,000 individually crafted, lead-like, drug-like small molecules.
Over the past 25 years the ChemDiv team has delivered hundreds of leads, drug candidates and new drug approvals in the areas of CNS, oncology, virology, inflammation, cardio and metabolic diseases to its pharma and biotech customers around the globe.
ChemDiv's integrated drug discovery and evaluation platforms allow for an accelerated, cost-effective R&D process aimed at rapidly bringing a project from target ID to Phase 3 clinical candidate and beyond.
SAN DIEGO, Calif., June 12, 2017 (SEND2PRESS NEWSWIRE) — ChemDiv Inc., a fully integrated California-based CRO, announced today that Arcus Biosciences selected ChemDiv as the sole source of molecules for Arcus’s growing HTS screening collection. This collaboration, which utilized Arcus’s medicinal chemistry knowledge and ChemDiv’s computational and synthetic chemistry expertise, has resulted in the selection of several hundred thousand structures from which Arcus expects to identify starting points for several of the discovery programs in its portfolio.
